Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease

Open Cardiovascular Medicine Journal

Volumn 5, Issue 1, 2011, Pages 110-116

  Tanindi, Asli ^a   Sahinarslan, Asife ^a   Elbeg, Sehri ^a   Cemri, Mustafa ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Coronary artery disease; Gensini score; Interleukin 6; Matrix metalloproteinase

Indexed keywords

GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GELATINASE B BLOOD LEVEL; GENSINI SCORE; HUMAN; INTERLEUKIN 6 BLOOD LEVEL; INTERSTITIAL COLLAGENASE BLOOD LEVEL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; TISSUE INHIBITOR OF METALLOPROTEINASE 1 BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 80053510622     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010110     Document Type: Article

References (23)

1. Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med 2010; 153: 387-95.
2. Arakaki PA, Marques MR, Santos MCLG. MMP-1 polymorphism and its relationship to pathological processes. J Biosci 2009; 34: 313-20.
3. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
4. Choudhary S, Higgins CL, Chen IY, et al. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissue. Arterioscler Thromb Vasc Biol 2006; 26: 2351-58.
5. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37: 235-9.
6. Amalinei C, Caruntu ID, Giuşça SE, Balan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010; 51: 215-28.
7. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-35.
8. Newby AC. Matrix metalloproteinases regulate migration, proliferation and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006; 69: 614-24.
9. Higo S, Uematsu M, Yamagishi M, et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: clinical evidence from distal protection. Circ J 2005; 69: 1180-5.
10. Libby P, Ridker PM. Inflammation and atherosclerosis: from population biology and bench research to clinical practice. J Am Coll Cardiol 2006; 48: A33-46.
11. Talukder MAH, Johnson WM, Varadharaj S, et al. Chronic cigarette smoking causes hypertension, increased oxidative stres, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice. Am J Physiol Heart Circ Physiol 2010; doi: 10.1152/ajpheart.00868.2010.
12. ohnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3,7,9 and 12 on atherosclerotic plaque stability in Mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005; 102: 15575-80.
13. Thomas AC, Newby AC. Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice. J Vasc Res 2010; 47: 299-308.
14. Etoh T, Joffs C, Deschamps AM, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001; 281: H987-94.
15. Brunner S, Kim JO, Methe H. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD+14 monocytes to progression of coronary artery disease. Am J Cardiol 2010; 105: 429-34.
16. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-pro BNP): measurement and relevance in heart failure. Vasc Health Risk Manag 2010; 6: 411-8.
17. Alehagen U, Lindstedt G, Eriksson H, et al. Utility of the aminoterminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem 2003; 49: 1337-46.
18. Omland T, de Lemos JA. Amino-terminal pro-B-type Natriuretic peptides in stable and unstable Ischemic heart disease. Am J Cardiol 2008; 101: 61A-6A.
19. Jarai R, Iordanova N, Jarai R, et al. Risk assessment in patients with unstable angina/non-ST elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur Heart J 2005; 26: 250-6.
20. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-30.
21. Yang D, Ma S, Li D, Tang B, Yang Y. Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium. Biochem Biophys Res Commun 2009; 388: 66-11.
22. Soejima H, Ogawa H, Sakamoto T, et al. Increased Serum matrix metalloproteinase-1 concentration predicts Advanced Left ventricular remodelling in patients with acute myocardial infarction. Circ J 2003; 67: 301-304.
23. Hwang JJ, Yang WS, Chiang FT, et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis 2009; 204: 293-7.